Qualigen Therapeutics (AIXC) & Its Competitors Head-To-Head Analysis

Qualigen Therapeutics (NASDAQ:AIXC) is one of 459 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its peers? We will compare Qualigen Therapeutics to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.

Volatility and Risk

Qualigen Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics’ peers have a beta of 5.76, meaning that their average share price is 476% more volatile than the S&P 500.

Profitability

This table compares Qualigen Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-52.57%
Qualigen Therapeutics Competitors	-2,662.44%	-364.10%	-42.99%

Institutional and Insider Ownership

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Qualigen Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
Qualigen Therapeutics Competitors	4899	9970	16004	378	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 66.80%. Given Qualigen Therapeutics’ peers stronger consensus rating and higher possible upside, analysts clearly believe Qualigen Therapeutics has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Qualigen Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Qualigen Therapeutics	N/A	-$6.26 million	-0.16
Qualigen Therapeutics Competitors	$432.23 million	-$67.62 million	-10.60

Qualigen Therapeutics’ peers have higher revenue, but lower earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Qualigen Therapeutics peers beat Qualigen Therapeutics on 9 of the 13 factors compared.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.